Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Shore Shares Promise of Relugolix for T-Suppression in Advanced Prostate Cancer

July 13th 2020

Neal D. Shore, MD, FACS, discusses the pivotal HERO trial, the promising safety data observed with relugolix, and the next steps for the agent in advanced prostate cancer.

Dr. Sartor on the Significance of the REASSURE Trial in mCRPC

July 10th 2020

Oliver Sartor, MD, discusses the significance of the REASSURE trial in patients with metastatic castration-resistant prostate cancer.

Experts Focus on 6 Life-Prolonging Treatments for mCRPC

July 9th 2020

During a recent OncLive Peer Exchange, a panel of experts in advanced prostate cancer provided their insights on how best to employ 6 therapies that are enabling men with mCRPC to live longer.

Dr. Morris on the Design of the Phase 3 CONDOR Trials in Recurrent Prostate Cancer

July 9th 2020

Michael J. Morris, MD, discusses the design of the phase 3 CONDOR trial in men with biochemically recurrent prostate cancer.

Dr. Katz on Redefining Risk Stratification in Prostate Cancer

July 9th 2020

Aaron E. Katz, MD, FACS, discusses redefining risk stratification for men with prostate cancer.

Emerging Therapies for Advanced Prostate Cancer

July 9th 2020

Radium-223 in Metastatic CRPC

July 9th 2020

Genetic Testing in Metastatic CRPC

July 9th 2020

Impact of Clinical Data on the Treatment of mCRPC

July 9th 2020

The CARD and PROfound Trials for Metastatic CRPC

July 9th 2020

Differences Between AR-Targeted Therapy in Prostate Cancer

July 9th 2020

Overall Survival Data Presented at ASCO 2020 for nmCRPC

July 9th 2020

FDA Approved Agents for Non-Metastatic CRPC

July 9th 2020

Clinical Trials in the Community Setting for Prostate Cancer

July 9th 2020

Data for Metastatic Castration-Sensitive Prostate Cancer

July 9th 2020

Conventional Versus PSMA Imaging in Prostate Cancer

July 9th 2020

PSMA-Targeted Imaging in Prostate Cancer

July 9th 2020

Neoadjuvant Apalutamide May Shrink Prostate Tumors

July 8th 2020

Interim data from a phase 2 study indicate that neoadjuvant hormone therapy may reduce tumor volume in men with high-risk prostate cancer planning to undergo radical prostatectomy.

Dr. Hope on the Effectiveness of 68Ga-PSMA-11 PET in Prostate Cancer

July 8th 2020

Thomas A. Hope, MD, discusses the positive findings from a phase 3 imaging study, which utilized 68Ga-PSMA-11 PET in the detection of pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer.

Dr. Shore on the Potential Utility of Relugolix in Advanced Prostate Cancer

July 8th 2020

Neal D. Shore, discusses the potential utility of relugolix in patients with advanced prostate cancer.